MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Emergent BioSolutions Inc

Închisă

SectorSănătate

7.34 0.27

Rezumat

Modificarea prețului

24h

Curent

Minim

7.28

Maxim

7.36

Indicatori cheie

By Trading Economics

Venit

99M

68M

Vânzări

33M

222M

Marjă de profit

30.603

Angajați

900

EBITDA

120M

133M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+51.77% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

62M

379M

Deschiderea anterioară

7.07

Închiderea anterioară

7.34

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Emergent BioSolutions Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 iul. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

FCC Approves U.S. Cellular Sale to T-Mobile

11 iul. 2025, 17:28 UTC

Principalele dinamici ale pieței

SharpLink Gaming Gains on Ethereum Purchase

11 iul. 2025, 16:57 UTC

Câștiguri

BASF Cuts Outlook on Global Economy Uncertainty

12 iul. 2025, 17:01 UTC

Câștiguri

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12 iul. 2025, 14:53 UTC

Câștiguri

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12 iul. 2025, 02:24 UTC

Achiziții, Fuziuni, Preluări

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 iul. 2025, 02:05 UTC

Achiziții, Fuziuni, Preluări

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 iul. 2025, 02:05 UTC

Achiziții, Fuziuni, Preluări

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 iul. 2025, 02:05 UTC

Achiziții, Fuziuni, Preluări

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 iul. 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 iul. 2025, 19:46 UTC

Achiziții, Fuziuni, Preluări

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 iul. 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 iul. 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 iul. 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 iul. 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 iul. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 iul. 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 iul. 2025, 16:42 UTC

Câștiguri

BASF Cuts Outlook on Global Economic Uncertainty

11 iul. 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 iul. 2025, 16:05 UTC

Câștiguri

BASF Will Publish Half-Year Results on July 30

11 iul. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11 iul. 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 iul. 2025, 16:03 UTC

Câștiguri

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 iul. 2025, 16:02 UTC

Câștiguri

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 iul. 2025, 16:01 UTC

Câștiguri

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 iul. 2025, 16:00 UTC

Câștiguri

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 iul. 2025, 15:59 UTC

Câștiguri

BASF Cuts 2025 Earnings View

11 iul. 2025, 15:58 UTC

Câștiguri

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 iul. 2025, 15:57 UTC

Câștiguri

BASF 2Q EBIT Before Special Items EUR810M

11 iul. 2025, 15:54 UTC

Câștiguri

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Comparație

Modificare preț

Emergent BioSolutions Inc Așteptări

Obiectiv de preț

By TipRanks

51.77% sus

Prognoză pe 12 luni

Medie 11.17 USD  51.77%

Maxim 15 USD

Minim 6.5 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEmergent BioSolutions Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.95 / N/ASuport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.